Guancydine
Based on 1 Customer Validation
Guancydine (Guancidine) is an orally active antihypertensive agent and vasodilator. Guancydine antagonizes the pressor effects of Angiotensin and Norepinephrine (HY-13715). Guancydine induces vasodilation in renal, mesenteric and cranial vascular beds, reduces peripheral resistance, increases cardiac output and lowers arterial blood pressure. Guancydine increases renal and forearm blood flow, reduces renal and forearm vascular resistance, alters cardiac systolic time, and reverses myocardial hypertrophy in hypertensive rats. Guancydine is applicable for research related to hypertension.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 98.0%
- CAS. Nr.: 1113-10-6
- Formel: C7H14N4
- Molecular Weight:154.21
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
GPCR/G Protein Compound Library
HY-L006
-
Neuronal Signaling Compound Library
HY-L013
-
Covalent Screening Library
HY-L036
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Orally Active Compound Library
HY-L061
-
Neurotransmitter Receptor Compound Library
HY-L062
-
Anti-Alzheimer's Disease Compound Library
HY-L069
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Antidepressant Compound Library
HY-L108
-
Coagulation and Anti-coagulation Compound Library
HY-L136
-
Antihypertensive Compound Library
HY-L145
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Anti-Drug-Resistant Compound Library
HY-L169
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Covalent Screening Library Plus
HY-L036P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
Alle Adrenergic Receptor Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Guancydine (8-30 mg/kg; p.o.) induces hypotension in hypertensive dogs at oral doses of 8-15 mg/kg, and causes hypotension, tachycardia and increased cardiac output in all experimental dogs at an oral dose of 30 mg/kg[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:normotensive dogs; hypertensive dogs; anesthetized dogs[2]
-
Dosage:8 mg/kg (p.o., single dose); 15 mg/kg (p.o., single dose); 30 mg/kg (p.o., single dose)
-
Administration:p.o.; single dose (8, 15, 30 mg/kg); i.p. (anesthetized dogs)
-
Result:Produced hypotension in hypertensive dogs (but not normotensive dogs) with no effect on heart rate at 8-15 mg/kg p.o.
Caused hypotension and tachycardia in all dogs at 30 mg/kg p.o.
Increased cardiac output in conscious dogs at 30 mg/kg p.o.
Caused vasodilation of the cranial mesenteric and renal vascular beds in anesthetized dogs via intraperitoneal administration.
Reduced renal vascular resistance in one conscious dog via oral administration.
Chemical Information
-
CAS. Nr. 1113-10-6
-
Appearance Solid
-
Molecular Weight 154.21
-
Formel C7H14N4
-
Color White to off-white
-
SMILES
N=C(NC(C)(C)CC)NC#N
-
Synonyms
Guancidine
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
DMSO : ≥ 125 mg/mL (810.58 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (13.49 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (13.49 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (271 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Hammer J, et al. Hemodynamic and therapeutic effects of guancydine in hypertension. Clin Pharmacol Ther. 1971 Jan-Feb;12(1):78-90. [Content Brief]
[2]. Cummings JR, et al. Cardiovascular actions of guancydine in normotensive and hypertensive animals. J Pharmacol Exp Ther. 1968 May;161(1):88-97. PMID: 4296847. [Content Brief]
[4]. Pettinger W, Sheppard H, Palkoski Z, Renyi E. Angiotensin antagonism and antihypertensive activity of phosphodiesterase inhibiting agents. Life Sci I. 1973 Jan 15;12(2):49-62. doi: 10.1016/0024-3205(73)90061-1. PMID: 4348855. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 6.4847 mL | 32.4233 mL | 64.8466 mL | 162.1166 mL |
| 5 mM | 1.2969 mL | 6.4847 mL | 12.9693 mL | 32.4233 mL | |
| 10 mM | 0.6485 mL | 3.2423 mL | 6.4847 mL | 16.2117 mL | |
| 15 mM | 0.4323 mL | 2.1616 mL | 4.3231 mL | 10.8078 mL | |
| 20 mM | 0.3242 mL | 1.6212 mL | 3.2423 mL | 8.1058 mL | |
| 25 mM | 0.2594 mL | 1.2969 mL | 2.5939 mL | 6.4847 mL | |
| 30 mM | 0.2162 mL | 1.0808 mL | 2.1616 mL | 5.4039 mL | |
| 40 mM | 0.1621 mL | 0.8106 mL | 1.6212 mL | 4.0529 mL | |
| 50 mM | 0.1297 mL | 0.6485 mL | 1.2969 mL | 3.2423 mL | |
| 60 mM | 0.1081 mL | 0.5404 mL | 1.0808 mL | 2.7019 mL | |
| 80 mM | 0.0811 mL | 0.4053 mL | 0.8106 mL | 2.0265 mL | |
| 100 mM | 0.0648 mL | 0.3242 mL | 0.6485 mL | 1.6212 mL |
Guancydine Related Classifications
HY-101554 Related Classifications
Powered by Bioz